Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Trials ; 6(6): 618-27, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19889888

ABSTRACT

BACKGROUND: Even though adverse event (AE) collection and official accounting are mandatory for clinical trials, there are limited detailed guidelines specifying how to summarize the event for reporting in a timely and expeditious manner. This article details the AE and serious adverse event (SAE) reporting summary developed for a large multi-center National Institutes of Health (NIH)-sponsored clinical trial. PURPOSE: To review and analyze the large volume of AE data reported by 10 sites (806 SAEs and 19,034 AEs from August 2000 to May 2007) the automated SAE summary was developed. It was designed to ensure timeliness and clarity in the complex process of AE review and reporting. METHODS: The AE and SAE case report forms (CRFs) as well as the automated SAE summary were developed within a database management system developed by the Data Coordinating Center (DCC) which allowed for web-based data entry at the DCC and 10 sites and offered immediate overall and site-specific reports accessible by the DCC, site, and NIH project staff. RESULTS: The automated SAE summary pulled data from multiple CRFs to create a succinct and informative summary and allowed for prompt and easy reporting to the regulatory agencies. The summary was adaptable to the needs of reviewers because of the availability of multiple search options.


Subject(s)
Adverse Drug Reaction Reporting Systems/organization & administration , Antiviral Agents/adverse effects , Electronic Data Processing/methods , Hepatitis C, Chronic/drug therapy , Interferon-alpha/adverse effects , Polyethylene Glycols/adverse effects , Randomized Controlled Trials as Topic/methods , Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/prevention & control , Database Management Systems , Disease Progression , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/mortality , Humans , Interferon alpha-2 , Interferon-alpha/therapeutic use , Liver Cirrhosis/etiology , Liver Cirrhosis/prevention & control , Liver Failure/etiology , Liver Failure/prevention & control , Liver Neoplasms/etiology , Liver Neoplasms/prevention & control , Multicenter Studies as Topic/methods , National Institutes of Health (U.S.) , Polyethylene Glycols/therapeutic use , Recombinant Proteins , Research Design , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...